Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  4,527 results for ""GASTRIC inhibitory polypeptide""

Your Filters

Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m 2 : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.

  • Authors : de Lemos JA; Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (J.A.d.L., W.V.).; Linetzky B

Subjects: Hypertension*/Hypertension*/Hypertension*/diagnosis ; Hypertension*/Hypertension*/Hypertension*/drug therapy ; Diabetes Mellitus, Type 2*

  • Source: Hypertension (Dallas, Tex. : 1979) [Hypertension] 2024 Apr; Vol. 81 (4), pp. e41-e43. Date of Electronic Publication: 2024 Feb 05.Publisher: Lippincott, Williams & Wilkins Country of Publication: United States NLM ID: 7906255 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues.

  • Authors : Sicinski KM; Department of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.; Sürmeli D

Subjects: Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/pharmacology ; Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/chemistry ; Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/Gastric Inhibitory Polypeptide*/metabolism

  • Source: Journal of medicinal chemistry [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4998-5010. Date of Electronic Publication: 2024 Mar 08.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.

  • Authors : Liuzzo G; Department of Cardiovascular and Pulmonary Sciences, Catholic University School of Medicine, Largo F.Vito 1, Rome 00168, Italy.; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo A. Gemelli 8, Rome 00168, Italy.

Subjects: Obesity* ; Diabetes Mellitus, Type 2* ; Glucagon-Like Peptide-2 Receptor*

  • Source: European heart journal [Eur Heart J] 2024 Apr 21; Vol. 45 (16), pp. 1392-1394.Publisher: Oxford University Press Country of Publication: England NLM ID: 8006263 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.

  • Authors : Jamal M; Department of Organ Transplant, College of Medicine, Health Sciences Center, Kuwait University, Kuwait City, Kuwait. .; The Clinic, Kuwait City, Kuwait. .

Subjects: Obesity, Morbid*/Obesity, Morbid*/Obesity, Morbid*/surgery ; Glucagon-Like Peptide-2 Receptor* ; Glucagon-Like Peptides*

  • Source: Obesity surgery [Obes Surg] 2024 Apr; Vol. 34 (4), pp. 1324-1332. Date of Electronic Publication: 2024 Mar 02.Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 9106714 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.

  • Authors : Urva S; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, IN, USA.; Levine JA

Subjects: Hypoglycemic Agents*/Hypoglycemic Agents*/Hypoglycemic Agents*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Gastric Inhibitory Polypeptide*

  • Source: Current medical research and opinion [Curr Med Res Opin] 2024 Apr; Vol. 40 (4), pp. 567-574. Date of Electronic Publication: 2024 Mar 12.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.

  • Authors : Ma J; Nanjing First Hospital Nanjing Medical University, Nanjing, China.; Liu M

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/chemically induced

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Apr; Vol. 26 (4), pp. 1454-1463. Date of Electronic Publication: 2024 Feb 01.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

  • Authors : Tobaiqy M; Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. .; Elkout H

Subjects: Liraglutide*/Liraglutide*/Liraglutide*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-2 Receptor*

  • Source: International journal of clinical pharmacy [Int J Clin Pharm] 2024 Apr; Vol. 46 (2), pp. 488-495. Date of Electronic Publication: 2024 Jan 24.Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Evidence that tirzepatide protects against diabetes-related cardiac damages.

  • Authors : Taktaz F; Department of Advanced Medical and Surgical Sciences, University of Campania ''Luigi Vanvitelli'', P.zza L. Miraglia, 2, 80138, Naples, Italy.; Scisciola L

Subjects: Heart Failure*/Heart Failure*/Heart Failure*/prevention & control ; Diabetes Mellitus*/Diabetes Mellitus*/Diabetes Mellitus*/diagnosis ; Diabetes Mellitus*/Diabetes Mellitus*/Diabetes Mellitus*/drug therapy

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Mar 30; Vol. 23 (1), pp. 112. Date of Electronic Publication: 2024 Mar 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.

  • Authors : Powell J; University of Florida College of Pharmacy, Gainesville, FL. Electronic address: .; Taylor J

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-2 Receptor* ; Gastric Inhibitory Polypeptide*

  • Source: Clinical therapeutics [Clin Ther] 2024 Mar; Vol. 46 (3), pp. 289-292. Date of Electronic Publication: 2024 Feb 02.Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.

  • Authors : Karakasis P; Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital 'Hippokration', Thessaloniki, Greece.; Patoulias D

Subjects: Albuminuria*/Albuminuria*/Albuminuria*/urine ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Mar; Vol. 26 (3), pp. 1090-1104. Date of Electronic Publication: 2023 Dec 20.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  4,527 results for ""GASTRIC inhibitory polypeptide""